These are some companies that might be interested in the results from the first Dog Years study.
Global Arthritis Drug Pipeline Rheumatoid Arthritis (RA) Pipeline
Drug Name
Company
Mechanism of Action
Development Phase
Target
Olokizumab
R-Pharm
IL-6 inhibitor
Phase III
IL-6
Filgotinib
Gilead/Galapagos
JAK1 inhibitor
Approved in EU/Japan, Phase III in US
JAK1
Fenebrutinib
Roche/Genentech
BTK inhibitor
Phase III
BTK
Otilimab
GSK
GM-CSF inhibitor
Phase III
GM-CSF
Deucravacitinib
Bristol Myers Squibb
TYK2 inhibitor
Phase II
TYK2
ATI-450
Aclaris
MK2 pathway inhibitor
Phase II
MK2
ABBV-599
AbbVie
JAK1 + BTK inhibitor
Phase II
JAK1/BTK
PF-06650833
Pfizer
IRAK4 inhibitor
Phase II
IRAK4
TJ202/MOR202
I-Mab
Anti-CD38 mAb
Phase II
CD38
BCD-089
Biocad
IL-6 inhibitor
Phase III
IL-6
Osteoarthritis (OA) Pipeline
Drug Name
Company
Mechanism of Action
Development Phase
Target
Lorecivivint
Biosplice Therapeutics
Wnt pathway modulator
Phase III
Wnt pathway
Tanezumab
Pfizer/Eli Lilly
NGF inhibitor
Phase III/Regulatory review
NGF
CNTX-4975
Centrexion
TRPV1 agonist
Phase III
TRPV1
LNA043
Novartis
ANGPTL3 protein
Phase II
Cartilage regeneration
MIV-711
Medivir
Cathepsin K inhibitor
Phase II
Cathepsin K
SM04690
Samumed
Wnt pathway inhibitor
Phase III
Wnt pathway
GLPG1972
Galapagos/Servier
ADAMTS-5 inhibitor
Phase II
ADAMTS-5
AMG 570
Amgen
ICOSL and BAFF inhibitor
Phase II
ICOSL/BAFF
NE-10
Novartis
IL-17 inhibitor
Phase II
IL-17
TPX-100
OrthoTrophix
Matrix protein
Phase II
Cartilage repair
Psoriatic Arthritis (PsA) Pipeline
Drug Name
Company
Mechanism of Action
Development Phase
Target
Deucravacitinib
Bristol Myers Squibb
TYK2 inhibitor
Phase III
TYK2
Bimekizumab
UCB
IL-17A/IL-17F inhibitor
Phase III
IL-17A/F
Sonelokimab
MorphoSys
IL-17A/F nanobody
Phase II
IL-17A/F
PF-06650833
Pfizer
IRAK4 inhibitor
Phase II
IRAK4
Namilumab
Izana Bioscience
GM-CSF inhibitor
Phase II
GM-CSF
BCD-085
Biocad
IL-17 inhibitor
Phase III
IL-17
Netakimab
BIOCAD
IL-17 inhibitor
Phase III
IL-17
KHK4827
Kyowa Kirin
IL-17 receptor A inhibitor
Phase III
IL-17RA
ABY-035
Affibody
IL-17 inhibitor
Phase II
IL-17
CC-90006
Bristol Myers Squibb
Anti-PD1 agonist antibody
Phase II
PD1
Ankylosing Spondylitis (AS) Pipeline
Drug Name
Company
Mechanism of Action
Development Phase
Target
Bimekizumab
UCB
IL-17A/IL-17F inhibitor
Phase III
IL-17A/F
Netakimab
BIOCAD
IL-17 inhibitor
Phase III
IL-17
Tofacitinib
Pfizer
JAK inhibitor
Phase III
JAK
Upadacitinib
AbbVie
JAK1 inhibitor
Phase III
JAK1
Risankizumab
AbbVie
IL-23 inhibitor
Phase III
IL-23
Filgotinib
Gilead/Galapagos
JAK1 inhibitor
Phase II
JAK1
BCD-085
Biocad
IL-17 inhibitor
Phase III
IL-17
Guselkumab
Janssen
IL-23 inhibitor
Phase III/IV
IL-23
Izokibep
Affibody/SOBI
IL-17A inhibitor
Phase II
IL-17A
Namilumab
Izana Bioscience
GM-CSF inhibitor
Phase II
GM-CSF
Disease-Modifying Osteoarthritis Drugs (DMOADs) in Development
Drug Name
Company
Mechanism of Action
Development Phase
Target
Sprifermin
Merck KGaA
Recombinant human FGF18
Phase II
Cartilage growth
TPX-100
OrthoTrophix
Matrix protein
Phase II
Cartilage repair
TLC599
TLC Biopharmaceuticals
Sustained-release dexamethasone
Phase III
Anti-inflammatory
JTA-004
Bone Therapeutics
Hyaluronic acid + plasma proteins
Phase III
Joint lubrication
Ampion
Ampio Pharmaceuticals
Anti-inflammatory
Phase III
Multiple inflammatory pathways
CNTX-6970
Centrexion
CCR2 antagonist
Phase II
CCR2
LNA043
Novartis
ANGPTL3 protein
Phase II
Cartilage regeneration
UBX0101
Unity Biotechnology
Senolytic agent
Phase II
Cellular senescence
Lorecivivint
Biosplice Therapeutics
Wnt pathway modulator
Phase III
Wnt pathway
ATB-346
Antibe Therapeutics
Hydrogen sulfide-releasing NSAID
Phase II
COX/H2S donor
Canine Arthritis Treatments in Development
Drug Name
Company
Mechanism of Action
Development Phase
Target
Librela (bedinvetmab)
Zoetis
Anti-NGF mAb
Approved
NGF
Frunevetmab
Zoetis
Anti-NGF mAb
Approved (Solensia)
NGF
Grapiprant
Elanco
EP4 receptor antagonist
Approved (Galliprant)
EP4 receptor
Ranevetmab
Nexvet/Zoetis
Anti-NGF mAb
Phase III
NGF
Ralicifeline
Zoetis
Anti-NGF mAb (for cats)
Phase III
NGF
Robenacoxib
Elanco
COX-2 inhibitor
Approved (Onsior)
COX-2
AT-016
Aratana Therapeutics
IL-31 mAb
Phase II
IL-31
CK9-28
CanineKinetics
Stem cell therapy
Phase II
Multiple
VetStem
VetStem Biopharma
Adipose-derived stem cells
Available
Multiple
Grapiprant
Elanco
EP4 receptor antagonist
Approved
EP4 receptor